Skip to content

Invest1 publisherNot yet confirmed elsewhere3 min readPublished

Korea's big five pharma put 12.4% of sales into R&D, and three of them set it by formula

Combined first-half research spending reached 562.8 billion won. Chong Kun Dang's 37% jump supplied nearly 40% of the group's increase, and the filings carry no profit lines to weigh it against.

The Investor · Invest desk

How we use AISend a correction

What happened

  • Korea's five largest drugmakers each spent around 100 billion won on R&D in the first half, according to semiannual reports released on the 23rd.
  • Daewoong reported the highest ratio, 115.7 billion won on 735.9 billion won of non-consolidated revenue, or 15.7%.
  • GC Biopharma raised R&D just 3.8% to 85.9 billion won, with an official crediting Aliglo profitability and the Curevo sale for the liquidity.

Compiled by The InvestorSomething wrong?How this is made

Why it matters

  • constraint When research is budgeted as a stated share of revenue, a weak sales half cuts the pipeline automatically; the spend is indexed to the top line rather than shielded from it.
  • contradiction GC Biopharma caps research at what liquidity allows and Hanmi commits to a floor of 13% to 15% regardless, so the sector's spending discipline is not one policy being read two ways.
  • decision With one company supplying nearly 40% of the group's increase off trial costs, anyone pricing the sector's research trend has to decide whether that is a durable step-up or a phase bulge, on...
  • exposure Neither the compression thesis nor the payoff can be tested from these documents, because the profit line that would settle it was not reported alongside the spending.

The cleanest figure in these filings is the one none of the five published. Add the disclosures up and first-half R&D across Yuhan, Chong Kun Dang, Hanmi, GC Biopharma and Daewoong comes to 562.8 billion won on 4.55 trillion won of revenue, or 12.4% of sales [12][13][14]. Reverse the reported growth rates and the comparable base a year earlier was about 486.1 billion won, so the group added roughly 76.7 billion won of research spending, up 15.8% [15]. Chong Kun Dang contributed about 30.4 billion won of that, close to 40% of the entire increment, from a company holding 20.4% of the group's revenue [16][17].

That concentration is worth reading carefully, because Chong Kun Dang's own explanation is not a strategy statement. A company official attributed the 36.6% rise to higher contract research and clinical trial costs [5][6]. Trial spending arrives with the phase, and it does not compound politely.

The three companies that did make strategy statements described R&D as a fixed claim on the top line rather than a residual. Yuhan said it concentrates roughly 10% of annual revenue on research and reported 10.5% for the half [3][4]. Hanmi said it has invested 13% to 15% of annual revenue each year and intends to hold that stance, and came in at 14.6% [7][8]. GC Biopharma said annual spending is planned to stay at around 9.5% to 10%, and landed at exactly 10.0% [10]. Budgets set that way are decided before the earnings line is known, which is the strongest available evidence that thinner margins here are chosen rather than suffered.

The framing of a tight 10% to 12% band does not survive the arithmetic. The reported ratios run from GC Biopharma's 10.0% to Daewoong's 15.7% [10][11], while the won amounts cluster inside a 1.46x range between 85.9 billion and 125.5 billion [18]. Spending is close to flat in absolute terms across five companies of different sizes, so the ratio is mostly telling you about the denominator. Daewoong's revenue is 62.9% of Yuhan's, and its research ratio is half again as high [20]. The denominators are also not the same animal: Yuhan's revenue is consolidated, Daewoong's is non-consolidated [3][11].

GC Biopharma is the useful outlier. Its increase was 3.8%, and its official credited improved Aliglo profitability and the sale of Curevo with securing the liquidity that funded it [10]. That is R&D paid for out of what came in, with a stated ceiling, sitting alongside Hanmi's declared floor. Same sector, opposite budgeting logic.

One caution on the margin story: these semiannual disclosures, filed on the 23rd, report revenue and research spending but no profit or margin figures [2][19]. The compression is an inference drawn from the spending side. What the documents actually establish is that the spending was set as policy, which makes the ratio, not the won total, the number that will show whether the policy held.

What to watch

  • Whether Hanmi commercializes Efe within this calendar year, the only dated commercial milestone attached to the group's spending.
  • Chong Kun Dang's full-year R&D figure, which shows whether the 36.6% rise was trial timing or a new base.
  • GC Biopharma's ratio in a half without asset-sale proceeds, against its stated 9.5% to 10% plan.
Loading claim ledger
Loading source directory links
Loading share composer
Loading topic controls
Loading related stories